{
  "@context": "https://tradecompliancerecords.com/schemas/v2/regulation.json",
  "schema_version": "2.2.0",
  "open_data": true,
  "ai_optimized": true,
  "slug": "eu-clinical-trials-regulation-2014",
  "name": "EU Clinical Trials Regulation 536/2014",
  "authority": "European Commission",
  "region": "EU",
  "cluster": "pharmaceutical",
  "wikidata_qid": null,
  "wikidata_entity": null,
  "wikipedia_article": null,
  "official_source_url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R0536",
  "gov_entry_url": null,
  "document_types": null,
  "key_obligations": null,
  "enforcement_bodies": null,
  "penalty_ranges": null,
  "affected_hs_codes": null,
  "mandatory_deadline": null,
  "applicability_scope": "Clinical trial material importers must maintain investigational medicinal product dossier — hash-verifiable.",
  "cryptographic_integrity": {
    "sha256_hash": "2dad331177aae8439294adc1a1a2df3336914d0eba9cab4ceb48a3d3d83972d0",
    "hash_algorithm": "SHA-256",
    "status": "cryptographically_hardened",
    "source_document_verified": true,
    "provenance": "source_document",
    "provenance_note": "SHA-256 derived from an ingested source document.",
    "r2_key": "regulations/eu-clinical-trials-regulation-2014/eu-clinical-trials-regulation-2014.html",
    "pdf_url": "https://tcr-vault.tradecompliancerecords.com/regulations/eu-clinical-trials-regulation-2014/eu-clinical-trials-regulation-2014.html",
    "file_size_bytes": 2035,
    "version_date": "2026-05-21",
    "last_verified_at": "2026-05-21T11:01:08.268Z"
  },
  "operational_consequences": null,
  "logistical_liability_exposure": false,
  "verification_consensus_score": "0",
  "verification_notes": null,
  "tcr_authority_page": "https://tradecompliancerecords.com/wiki/eu-clinical-trials-regulation-2014",
  "created_at": "2024-01-01",
  "infographic_r2_key": null,
  "infographic_sha256_hash": null,
  "infographic_generated_at": null,
  "infographic_approved": 0,
  "origin_problem": "FACTUAL: 2009 TeGenero TGN1412 clinical trial incident (6 severe adverse reactions, UK) highlighted inadequate EU oversight on clinical trials.",
  "problem_statement": "HEADLINE: Fragmented EU clinical trial oversight led to inconsistent safety and efficacy evaluations.",
  "pre_regulation_status_quo": "FACTUAL: No centralized EU database for clinical trial applications. National authorities operated independently without harmonized standards.",
  "operational_pain_points": [
    "Article 25: Centralized EU portal submission required — avg 12 data fields per trial application.",
    "Article 31: Ethics committee approval mandatory — avg 60-day review period.",
    "Article 50: Safety reporting — 7-day timeline for serious adverse events.",
    "Article 81: Public disclosure of trial results — 12-month deadline post-study.",
    "Article 57: Dossier maintenance — hash-verifiable documentation required for all investigational products."
  ],
  "search_intent_tree": null,
  "paa_questions": [
    {
      "q": "What are the penalties for non-compliance with EU Clinical Trials Regulation 536/2014?",
      "a": "• Max penalty: Not publicly specified\n• Trigger: Non-compliance with Article 50 safety reporting\n• Enforcement body: European Medicines Agency\n• First offence vs repeat: Not publicly specified"
    },
    {
      "q": "Who must comply with EU Clinical Trials Regulation 536/2014?",
      "a": "• Threshold: Not publicly specified\n• Entity types: Clinical trial sponsors, importers\n• Exemptions: Not publicly specified\n• Geographic scope: EU member states"
    },
    {
      "q": "What is the compliance deadline for EU Clinical Trials Regulation 536/2014?",
      "a": "• Phase 1 deadline: 31 January 2022 for new trials\n• Phase 2 deadline: 31 January 2023 for ongoing trials\n• Transitional period: 1 year\n• Enforcement start: 31 January 2022"
    },
    {
      "q": "What documents are required for EU Clinical Trials Regulation 536/2014 compliance?",
      "a": "• Investigational Medicinal Product Dossier: Product details + Article 25\n• Clinical Trial Application Form: Trial specifics + Article 31\n• Retention period: 25 years\n• Submission format: Electronic via EU portal"
    },
    {
      "q": "How does EU Clinical Trials Regulation 536/2014 affect importers?",
      "a": "• Maintain investigational medicinal product dossier — Article 57\n• Customs declaration requirement: Not publicly specified\n• Due diligence or traceability requirement: Not publicly specified\n• Cost estimate: Not publicly specified"
    },
    {
      "q": "What is the enforcement mechanism for EU Clinical Trials Regulation 536/2014?",
      "a": "• Primary enforcer: European Medicines Agency\n• Investigation trigger: Complaint or audit\n• Appeal process: Article 85\n• Cross-border coordination: EU member state collaboration"
    },
    {
      "q": "Are there exemptions under EU Clinical Trials Regulation 536/2014?",
      "a": "• SME exemption: Not publicly specified\n• Sector exclusions: Not publicly specified\n• Transitional exemptions: Not publicly specified\n• Article reference: Not publicly specified"
    },
    {
      "q": "How does EU Clinical Trials Regulation 536/2014 interact with other regulations?",
      "a": "• Overlaps with: EU Good Clinical Practice Directive\n• Conflicts with: Not publicly specified\n• Supersedes: Directive 2001/20/EC\n• Mutual recognition: Not publicly specified"
    },
    {
      "q": "What supply chain traceability does EU Clinical Trials Regulation 536/2014 require?",
      "a": "• Tier depth: Not publicly specified\n• Data fields required: Not publicly specified\n• Technology standard: Not publicly specified\n• Audit frequency: Not publicly specified"
    },
    {
      "q": "What is the cost of EU Clinical Trials Regulation 536/2014 compliance for a mid-size company?",
      "a": "• Implementation cost: Not publicly specified\n• Annual compliance cost: Not publicly specified\n• Penalty risk: Not publicly specified\n• Source: Not publicly specified"
    }
  ],
  "enrichment_status": "enriched"
}